NVCR
NovoCure LimitedstockNASDAQ
Market OpenNov 19, 2026 3:44:14 PM EST
10.69USD-0.419%(-0.04)1,007,761
NVCR News
FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors. ·
The Motley Fool+1 source
NovoCure denied FDA approval of Optune Mya for brain metastases ·
Seeking Alpha
Novocure’s device for treating brain metastases rejected by FDA ·
Medical Device Network
Novocure denied FDA approval for metastatic cancer treatment ·
MedTech Dive
NovoCure: 3 Key Takeaways for Long-Term Investors ·
The Motley Fool+1 source
NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript ·
Seeking Alpha
NovoCure slips despite quarterly beats, updated guidance ·
Seeking Alpha
NovoCure (NVCR) Q3 2026 Earnings Call Transcript ·
The Motley Fool
NovoCure Q3 2026 Earnings Preview ·
Seeking Alpha
